for their contribution to the manuscript: Pek Kuen Liew and Ngee Siang Lau for their help with performing the flow cytometry analysis, and Kim Wah Ho, Jerome Teen Chuen Tan, Syed Abdul Kadir Sharifah Shahnaz, and Ngee Siang Lau for managing this patient and supervising the writing of this manuscript.

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-97.
2. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014;123:843-50.
3. Rousselot P, Couëd MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 2016;128:774-82.
4. Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 2018;5:e16-18.
5. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357-66.
6. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015;125:3711-9.
7. Foà R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 2020;383:1613-8.
8. Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449-59.
9. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 2017;35:1795-802.
10. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740-53.
11. Weiss MA, Aliff TT, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 2002;95:581-7.
12. Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 2016;122:2941-51.

A rare case of primary plasma cell leukemia exhibiting the small-cell variant of plasma cells

TO THE EDITOR: Plasma cell leukemia (PCL) is a rare disease that accounts for approximately 2% of all plasma cell myeloma (PCM) cases. It is defined as the presence of clonal plasma cells (PCs) in more than 20% of the total nucleated cells (TNCs) or when absolute TNC count is higher than 2×10⁹/L in the peripheral blood. Primary PCL (pPCL) is the initial leukemic presentation of myeloma, which represents 60% of PCL cases [1]. Although patients with PCLs generally have a poor prognosis, early and aggressive chemotherapy and stem cell transplantation (SCT) may improve the prognosis [2]. Clonal PCs can appear in an atypical form, such as small-cell, cleaved, polymorphous, asynchronous, or blastic types, in addition to the Marshalko type, which is indistinguishable from a typical PC [3]. Therefore, the accurate identification of neoplastic PCs in the bone marrow and peripheral blood is important. Herein, we report a case of pPCL that was diagnosed by flow cytometry (FCM) due to morphological similarities between the clonal PCs and small-mature lymphocytes. This study was reviewed and approved by the institutional review board of Soonchunhyang University Hospital in Seoul, South Korea (IRB No. 2021-09-007).

In December 2019, a 65-year-old man visited the emergency room at Soonchunhyang University Seoul Hospital with acute chest pain. No specific abnormalities were observed in the lungs or on cardiovascular examination. The initial complete blood count (CBC) revealed pancytopenia as follows: Hb, 47 g/L (120–160 g/L); WBC, 2.8×10⁹/L (4.0–10.0×10⁹/L); and platelet count, 45×10⁹/L (130–450×10⁹/L). Peripheral blood smears demonstrated small-mature lymphoid cells, which accounted for up to 20% of the TNCs (Fig. 1A), and bone marrow aspirate smears revealed lymphoid cells comprising 88% of the TNCs (Fig. 1B) together with occasional multinucleated atypical lymphoid cells (Fig. 1C, D). Immunophenotype analysis by FCM (Navios EX flow cytometer and Kaluza analysis software, Beckman Coulter, Inc., Miami, FL, USA) of the bone marrow and peripheral blood specimens revealed abnormal PC populations accounting for 80% and 20% of TNCs, respectively. CD45+/CD19-/CD20+/CD38+/CD138-/CD56-/CD117+/cCD79a+/FMC7+ cells and cytoplasmic lambda light chain restriction (Fig. 2) was observed. Serum protein electrophoresis (PEP)
and immunofixation electrophoresis (IFE) detected monoclonal gammopathy of the IgA and lambda types (M protein, 4.7 g/L). In the quantitative serum immunoglobulin test by an immunoturbidimetric assay (cobas c702 analyzer, Roche, Ibaraki, Japan; cobas ALB2 reagent, Mannheim, Germany), the IgA and free lambda light-chain were measured as 6.44 g/L (7.0–40.0 g/L) and 0.095 g/L (0.057–0.263 g/L), respectively. In the urine PEP and IFE, lambda-type Bence–Jones proteinuria was detected with an M-protein level of 0.12 g/L. FISH analysis (Fig. 1E) demonstrated IGH-CCND1 rearrangement and p53 (17p) deletion (dual-fusion probe, designed by Cytocell, Cambridge, UK and Metafer/Zeiss system, Metasystems, Altlussheim, Germany), and next-generation sequencing (NGS) identified suspected pathogenic mutations of TP53 (c.490A>G, p.Lys164Glu) (customized panel designed by Cellemics, Inc., Seoul, Korea). On the basis of these results, the patient was diagnosed with pPCL.

Allogenic hematopoietic SCT was performed after the patient achieved complete remission with chemotherapy (carfilzomib, lenalidomide, and dexamethasone). Nevertheless, the patient succumbed to death due to pneumonia 5 months after undergoing the SCT.

Small-cell-type PCs are small (mean size of 13 µm; compared with 21 µm for the Marschalko type) and have a round shape with only a narrow rim of a cytoplasm. Their nuclei have dense chromatin with rare nucleoli and mitoses resembling those of small lymphocytes [3]. Given their morphological similarities, the microscopic detection of small-cell-type PCL may be challenging to discriminate from small mature lymphocytes. While neoplastic PCs of PCM usually exhibit the CD19+/CD45variable+/CD38+/CD56– immunophenotype, neoplastic PCs of PCL exhibit a more-fre-
Fig. 2. Flow-cytometric immunophenotyping of the small-cell type of plasma cell leukemia. Clonal plasma cells in the bone marrow exhibited a CD19-/CD20+/CD38+/CD56-/CD138+ phenotype and cytoplasmic lambda light-chain restriction gated by CD45- and low side scatter.

Table 1. Basic clinical characteristics of six patients with small-cell-type plasma cell leukemia.

| Sex/age (yr) | Initial CBC | Plasma cells (BM/PB), % | Immunophenotyping results | PEPE/IFE | Cytogenetic study | Molecular study | Disease course |
|-------------|-------------|------------------------|--------------------------|----------|----------------|-----------------|---------------|
| M/65        | WBC: 2.8×10^9/L Hb: 47 g/L Platelet: 45×10^9/L | > 80.0 20.0 | CD45-/CD19-/CD20+/CD38+/CD56-/CD138+/CD117 | IgA-lambda (5 g/L) | 42,XY,-1,-9,-10, t(11;14)(q13;q22), t(1;19)(p11.2;q11.2), + mar[46], XY[14] | IGH/CCND1 rearrangement, 13q[14 deletion, p53[17p deletion, P53 (c.490A > G), p.Lysx164Gluf] | Died after 5 months after allo-PBSCT |
| F/59        | NR          | > 80.0 40.0           | CD45-/CD20-/CD38+ CD138+/CD56-/CD117 | IgG-lambda (40 g/L) | (45,XX) | Overexpression of A454/CD20 and CCND2 | NR |
| M/74        | NR          | > 80.0 52.0           | CD45-/CD19-/CD20+/CD38+/CD117 | IgG-lambda (30 g/L) | (46,XY) | Overexpression of CCND1 | CR after CTx |
| M/61        | WBC: 12.3×10^9/L Hb: 98 g/l Platelet: 89×10^9/L | 54.0 22.7 | CD45-/CD19-/CD20+/CD38+/CD138-/CD117 | Lambda: 97.38% Kappa: 0.14% | Hyperdiploid clone with trisomy 2, 3, 12, and 18 | Overexpression of CCND1 | Died 3 months after diagnosis |
| F/77        | WBC: 8.6×10^9/L Hb: 101 g/l Platelet: 140×10^9/L | 90.0 43.5 | CD45-/CD19-/CD20+/CD38+/CD138-/CD117 | Lambda: 97.38% Kappa: 0.14% | Hyperdiploid clone with trisomy 2, 3, 12, and 18 | Overexpression of CCND1 | CR after CTx |
| F/85        | WBC: 28.2×10^9/L Hb: 92 g/l Platelet: 238×10^9/L | 75.0 74.0 | CD45-/CD19-/CD20+/CD38+/CD138-/CD117 | Lambda: 97.38% Kappa: 0.14% | Hyperdiploid clone with trisomy 2, 3, 12, and 18 | Overexpression of CCND1 | CR after CTx |
| Gounari et al. [8] | NR | NR | CD45-/CD19-/CD20+/CD38+/CD138-/CD117 | IgG-lambda (40 g/L) | (46,XY) | Overexpression of CCND1 | NR |
| Loureiro et al. [9] | NR | NR | CD45-/CD19-/CD20+/CD38+/CD138-/CD117 | Lambda: 97.38% Kappa: 0.14% | Hyperdiploid clone with trisomy 2, 3, 12, and 18 | Overexpression of CCND1 | NR |
| Teriaky et al. [10] | NR | NR | CD45-/CD19-/CD20+/CD38+/CD138-/CD117 | Lambda: 97.38% Kappa: 0.14% | Hyperdiploid clone with trisomy 2, 3, 12, and 18 | Overexpression of CCND1 | NR |

*Amount of M protein. Results of the FISH, NGS study, gene expression profiling (GEP) analysis, and immunohistochemical staining. Abbreviations: allo-PBSCT, allogeneic peripheral blood stem cell transplantation; CBC, complete blood count; CR, complete remission; CTx, chemotherapy; IFE, immunofixation electrophoresis; NR, not reported; PEP, protein electrophoresis.
quent expression of CD20 and a less-frequent expression of CD56 [4, 5]. Several myeloma studies have shown that CD20 expression is associated with small-cell-type neoplastic PCs and t(11;14) in PCM [6, 7]. As CD56 is an adhesion molecule, PCs with no CD56 expression may reduce cell-to-cell interactions, easily escape from the bone marrow, invade extramedullary organs, including the peripheral blood, and proliferate abnormally beyond immune surveillance [4, 5].

To date, only 5 cases of small-cell-type PCL (Table 1) have been reported, while clonal PCs of the small-cell-type are found only in 3.4% of PCM [7-10]. The median age of the 6 cases including ours was 70.2 years with no demographic preponderance. The 6 cases of small-cell-type PCL demonstrated a variable expression of CD20 and loss of CD56. t(11;14) (IGH/CCND1 rearrangement), and overexpression of CCND1 or CCND2 was detected in 5 cases. Their secreting components were IgG or IgA with lambda or kappa light chains, including only one kappa light chain. The amount of M protein was not associated with the tumor burden. Two patients died within a year of starting chemotherapy.

In summary, we report a rare case of pPCL with t(11;14) presenting as the small-cell type. When diagnosing PCL of an atypical plasma cell type, it is mandatory to use FCM immunophenotyping for the bone marrow and peripheral blood specimens with morphology and IFE.

Jung-Ah Kim1, Woo Yong Shin1, Jeun Kim1, Hae In Bang1, Seug Yun Yoon2, Rojin Park1
1Department of Laboratory Medicine, 2Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea

Correspondence to: Rojin Park
Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, 59 Daeagwan-ro, Yongsan-gu, Seoul 04401, Korea
E-mail: rpark@schmc.ac.kr

Acknowledgments
This study was supported by research funding from Soonchunhyang University.

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014;124:907-12.
2. Mina R, Joseph NS, Kaufman JL, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer 2019;125:416-23.
3. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-55.
4. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010;149:334-51.
5. Pellat-Deceunynck C, Barilé S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12:1977-82.
6. Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003;102:1070-1.
7. Heerema-McKenney A, Waldron J, Hughes S, et al. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol 2010;133:265-70.
8. Gounari E, Kaiafa G, Koletsa T, et al. CD5+ B lymphoproliferative disorder with subsequent development of plasma cell leukaemia: diagnostic and aetiologic reasoning. Cytometry B Clin Cytom 2018;94:688-94.
9. Loureiro AD, Gonçalves MV, Ikoma MR, et al. Plasma cell leukemia mimicking chronic lymphocytic leukemia. Blood 2011;117:2991.

Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease

TO THE EDITOR: Alterations of the tumor suppressor gene TP53 are frequent in Diffuse Large B-cell Lymphoma (DLBCL), the most commonly diagnosed blood cancer at over 30,000 diagnoses per year, and are associated with poor prognosis [1]. DLBCL has traditionally been divided into three cell of origin (COO) subcategories based on RNA expression profiles or IHC: Activated B-cell (ABC), Germinal Center B-cell (GCB), and Unclassified cases [2]. Patients with ABC tumors are characterized by a more aggressive profile alongside active NF-κB and BCR signaling pathways, while GCB cases are associated with alterations that drive aberrant chromatin-modification, PI3K signaling, and the upregulation MYC and BCL2 through structural variants...